SLC5A2 and type 2 diabetes mellitus: Figure 5 showed the curve of effects from SGLT-2 inhibitors on UACR in T2DM patients, where the treatment duration to reach 25%, 50%, 75%, and 80% Emax was 0.150 weeks, 0.448 weeks, 1.344 weeks, and 1.792 weeks, respectively.